Director Frances Arnold filed a Form 4 with the SEC on November 4, 2026, disclosing the sale of 11,409 shares of Generate Biomedicines, Inc. common stock on October 29, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 11,409 shares of common stock were disposed of on October 29, 2026, with transaction code S.
  • Weighted average price: The reported sale price was $16.1919 per share, a weighted average of multiple transactions ranging from $16.00 to $16.45 per share, inclusive.
  • 10b5-1 plan: The transactions were executed under a Rule 10b5-1 trading plan adopted by Arnold on March 13, 2026.
  • Direct holdings after transaction: Arnold directly holds 220,063 shares of common stock following the reported sale.
  • Indirect holdings: Arnold also indirectly holds 232,472 shares through The Frances Arnold 2010 Irrevocable Trust, though she disclaims beneficial ownership of those shares for Section 16 purposes except to the extent of any pecuniary interest.

Generate Biomedicines Director Arnold Reports October 2026 Share Sale

According to the Form 4 filing, Frances Arnold, a director of Generate Biomedicines, Inc. (NASDAQ:GENB), sold 11,409 shares of common stock on October 29, 2026. The filing states that the sale was carried out pursuant to a Rule 10b5-1 trading plan that Arnold adopted on March 13, 2026. The form was signed by Michael Wolf as Attorney-in-Fact and filed on November 4, 2026.

The filing reports a weighted average sale price of $16.1919 per share. According to footnote 2, the shares were sold across multiple transactions at prices ranging from $16.00 to $16.45 per share, inclusive. Arnold undertakes, per the filing, to provide full information on the number of shares sold at each separate price upon request by the issuer, any security holder, or the SEC staff.

Following the reported transaction, Arnold directly holds 220,063 shares. The filing also discloses 232,472 shares held indirectly through The Frances Arnold 2010 Irrevocable Trust. The filing notes that Arnold "disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of her pecuniary interest therein, if any," and that the report "shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."

What Was Disclosed

Frances Arnold, a director at Generate Biomedicines, Inc., disclosed the sale of 11,409 shares of common stock on October 29, 2026, at a weighted average price of $16.1919, executed under a pre-established 10b5-1 trading plan adopted March 13, 2026.